Biotechnology Stock News
Categories
- All
- Editor's Picks
- Stock Market News
- Q&A with Gurus
- Gurus' Stock Picks
- Insider Transaction
- Earning Reports
- CEO Shareholder Letters
- Press Release
- Earnings Call Transcripts
- Podcast
Industries
- Aerospace & Defense
- Agriculture
- Asset Management
- Banks
- Beverages - Alcoholic
- Beverages - Non-Alcoholic
- Biotechnology
- Building Materials
- Business Services
- Capital Markets
- Chemicals
- Conglomerates
- Construction
- Consumer Packaged Goods
- Credit Services
- Diversified Financial Services
- Drug Manufacturers
- Education
- Farm & Heavy Construction Machinery
- Forest Products
- Furnishings, Fixtures & Appliances
- Hardware
- Healthcare Plans
- Healthcare Providers & Services
- Homebuilding & Construction
- Industrial Distribution
- Industrial Products
- Insurance
- Interactive Media
- Manufacturing - Apparel & Accessories
- Media - Diversified
- Medical Devices & Instruments
- Medical Diagnostics & Research
- Medical Distribution
- Metals & Mining
- Oil & Gas
- Other Energy Sources
- Packaging & Containers
- Personal Services
- Real Estate
- REITs
- Restaurants
- Retail - Cyclical
- Retail - Defensive
- Semiconductors
- Software
- Steel
- Telecommunication Services
- Tobacco Products
- Transportation
- Travel & Leisure
- Utilities - Independent Power Producers
- Utilities - Regulated
- Vehicles & Parts
- Waste Management
GuruFocus Research Biotechnology
Lexicon Pharmaceuticals Inc (LXRX) Q1 2024 Earnings Call Transcript Highlights: Navigating Challenges and Capitalizing on Strategic Opportunities
Despite a net loss, Lexicon Pharmaceuticals Inc (LXRX) shows promising advancements in drug development and strategic financial maneuvers. May 03, 2024
GuruFocus Research Biotechnology
Zymeworks Inc (ZYME) (Q1 2024) Earnings Call Transcript Highlights: Navigating Challenges and Advancing Clinical Trials
Despite a rise in net loss and a drop in revenue, Zymeworks Inc (ZYME) remains optimistic with strong cash reserves and strategic advancements in global clinical trials. May 03, 2024
GuruFocus Research Biotechnology
Vir Biotechnology Inc (VIR) (Q1 2024) Earnings Call Transcript Highlights: Navigating Challenges and Capitalizing on Clinical Advancements
Despite a dip in revenue, VIR showcases robust clinical progress and strategic regulatory engagements, underpinned by a strong cash reserve. May 03, 2024
GuruFocus Research Biotechnology
Puma Biotechnology Inc (PBYI) Q1 2024 Earnings Call Transcript Highlights: A Detailed Review of Financial and Operational Performance
Insights into Puma Biotechnology's Q1 2024 earnings, strategic initiatives, and future outlook amidst fluctuating revenues and expanding global presence. May 03, 2024
GuruFocus Research Biotechnology
Codexis Inc (CDXS) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and Strategic Advances
Explore key financial outcomes and strategic milestones from Codexis Inc's first quarter of 2024, reflecting robust growth and promising developments. May 03, 2024
GuruFocus Research Biotechnology
Kymera Therapeutics Inc (KYMR) (Q1 2024) Earnings Call Transcript Highlights: Strategic Progress and Financial Health
Explore key insights from Kymera Therapeutics' Q1 2024 earnings, emphasizing robust financial standing and promising pipeline developments. May 03, 2024
GuruFocus Research Biotechnology
Regeneron Pharmaceuticals Inc (REGN) Q1 2024 Earnings Call Transcript Highlights: Key Financial Achievements and Strategic Insights
Discover how Regeneron sustains robust growth with significant advancements in clinical programs and strategic market maneuvers. May 03, 2024
GuruFocus Research Biotechnology
Agios Pharmaceuticals Inc (AGIO) (Q1 2024) Earnings Call Transcript Highlights: Strategic Advances and Robust Financial Position
Agios Pharmaceuticals showcases a strong Q1 with significant progress in clinical trials and a solid cash reserve, setting the stage for future growth. May 03, 2024